Apollo Medical Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Revenue by Major Customers by Reporting Segments

The Company had major payors that contributed the following percentage of net revenue:

	For The Three Months Ended March 31,
	2018			2017

Payor A		*	%		12.9	%
Payor B		12.0	%		24.0	%
Payor C		*	%		11.9	%
Payor D		10.9	%		12.7	%

* Less than 10% of total net revenues

The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts:

	As of March 31, 2018			As of December 31, 2017

Payor D		25.6	%		23.8	%
Payor E		38.2	%		30.5	%

Fair Value Measurements, Recurring and Nonrecurring

The carrying amounts and fair values of the Company’s financial instruments as of March 31, 2018 are presented below:

	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets
Money market accounts*	$	42,300,818	$	-	$	-	$	42,300,818
Marketable securities certificates of deposit		1,061,022		-		-		1,061,022
Marketable securities equity securities		77,455		-		-		77,455

Total	$	43,439,295	$	-	$	-	$	43,439,295

The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2017 are presented below:

	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets
Money market accounts*	$	41,231,405	$	-	$	-	$	41,231,405
Marketable securities certificates of deposit		1,057,090		-		-		1,057,090
Marketable securities equity securities		86,005		-		-		86,005

Total	$	42,374,500	$	-	$	-	$	42,374,500

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation

The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017:

	Derivative Assets (Warrants)

Balance at January 1, 2017	$	5,338,886
Change in fair value of warrant liabilities		1,522,222
Balance at March 31, 2017	$	6,861,108

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details